SpringWorks Therapeutics Announces Approval of Merger Agreement with Merck KGaA, Expects Completion in Second Half of 2025

Reuters

16 Jun

SpringWorks <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Approval of Merger Agreement with <a href="https://laohu8.com/S/MKGAF">Merck KGaA</a>, Expects Completion in Second Half of 2025

SpringWorks Therapeutics Inc. has announced an update regarding its merger with Merck KGaA, Darmstadt, Germany. According to the company, the Merger Agreement, which was initially disclosed on April 27, 2025, has been approved by SpringWorks' board of directors. Under the agreement, EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, will merge with SpringWorks, resulting in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger is anticipated to be completed in the second half of 2025, pending satisfaction of customary closing conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-059579), on June 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2543675797"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2543675797\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2543675797?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-16 18:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2543675797","market":"us","top_or_hot":-1,"title":"SpringWorks Therapeutics Announces Approval of Merger Agreement with Merck KGaA, Expects Completion in Second Half of 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Approval of Merger Agreement with <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a>, Expects Completion in Second Half of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SpringWorks Therapeutics Inc. has announced an update regarding its merger with <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a>, Darmstadt, Germany. According to the company, the Merger Agreement, which was initially disclosed on April 27, 2025, has been approved by SpringWorks' board of directors. Under the agreement, EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, will merge with SpringWorks, resulting in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger is anticipated to be completed in the second half of 2025, pending satisfaction of customary closing conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-059579), on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SpringWorks Therapeutics Announces Approval of Merger Agreement with Merck KGaA, Expects Completion in Second Half of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSpringWorks Therapeutics Announces Approval of Merger Agreement with Merck KGaA, Expects Completion in Second Half of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-16 18:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      SpringWorks <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Approval of Merger Agreement with <a href=\"https://laohu8.com/S/MKGAF\">Merck KGaA</a>, Expects Completion in Second Half of 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        SpringWorks Therapeutics Inc. has announced an update regarding its merger with <a href=\"https://laohu8.com/S/MKKGY\">Merck KGaA</a>, Darmstadt, Germany. According to the company, the Merger Agreement, which was initially disclosed on April 27, 2025, has been approved by SpringWorks' board of directors. Under the agreement, EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, will merge with SpringWorks, resulting in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger is anticipated to be completed in the second half of 2025, pending satisfaction of customary closing conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-059579), on June 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SWTX","symbol_name":"SpringWorks Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDL1tDbSg:1","article_id":"2543675797","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2543675797","pubTimestamp":1750068944,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"SpringWorks Therapeutics Inc. has announced an update regarding its merger with Merck KGaA, Darmstadt, Germany. According to the company, the Merger Agreement, which was initially disclosed on April 27, 2025, has been approved by SpringWorks' board of directors. Under the agreement, EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, will merge with SpringWorks, resulting in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger is anticipated to be completed in the second half of 2025, pending satisfaction of customary closing conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Elect","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SWTX":"SpringWorks Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"SpringWorks Therapeutics宣布批准与Merck KGaA的合并协议，预计2025年下半年完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SWTX":0.9},"content_text":"SpringWorks Therapeutics Announces Approval of Merger Agreement with Merck KGaA, Expects Completion in Second Half of 2025\n    \n\n        SpringWorks Therapeutics Inc. has announced an update regarding its merger with Merck KGaA, Darmstadt, Germany. According to the company, the Merger Agreement, which was initially disclosed on April 27, 2025, has been approved by SpringWorks' board of directors. Under the agreement, EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, will merge with SpringWorks, resulting in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger is anticipated to be completed in the second half of 2025, pending satisfaction of customary closing conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-059579), on June 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}